RSVPreF3-AS01E | Clinical Trials Search

找到 121 条关于 “RSVPreF3-AS01E”

需要更精确的结果？

可按分期、招募状态、国家、申办方、年龄和研究类型筛选。

高级筛选临床试验

Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons

计划入组 170 人 · 首次发布于 2025 年 7 月 3 日

An Extended Follow up of a RTS,S/AS01E Malaria Vaccine Trial

计划入组 450 人 · 首次发布于 2009 年 4 月 1 日

A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control

计划入组 3,855 人 · 首次发布于 2023 年 1 月 30 日

A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above

计划入组 386 人 · 首次发布于 2023 年 6 月 27 日

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above

计划入组 1,459 人 · 首次发布于 2024 年 4 月 29 日

进行中（未招募）

A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant

计划入组 168 人 · 首次发布于 2025 年 7 月 30 日

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above

计划入组 1,544 人 · 首次发布于 2022 年 10 月 21 日

Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV

计划入组 402 人 · 首次发布于 2020 年 9 月 21 日

A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD)

计划入组 751 人 · 首次发布于 2024 年 9 月 26 日

Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

计划入组 26,675 人 · 首次发布于 2021 年 5 月 14 日

第 1 页，共 10 页